Where does Denali Therapeutics Inc.'s cash flow data come from?

Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$508.02M+0.9%	-$512.54M-2.8%	-$498.74M-4.1%	-$479.03M-5.5%	-$453.94M-7.4%
Depreciation and amortization	$11.7M+4.6%	$11.18M+10.0%	$10.17M+12.2%	$9.06M+13.9%	$7.96M+2.1%
Stock-based compensation	$97.56M-2.1%	$99.63M-1.1%	$100.76M+0.3%	$100.49M+0.3%	$100.2M-2.6%
Net cash from operating activities	-$412.34M+0.1%	-$412.6M-3.7%	-$397.78M-13.8%	-$349.62M+4.4%	-$365.54M-5.1%
Capital expenditures	——	——	——	$18.33M-2.7%	$18.84M+18.4%
Net cash from investing activities	$330.99M+29.7%	$255.28M—	——	——	——
Net cash from financing activities	$412.02M+118%	$189.22M—	——	——	——
Net increase (decrease) in cash	$330.68M+937%	$31.9M+1,617%	$1.86M—	——	——
Free cash flow	-$419.23M+0.7%	-$422.1M-2.7%	-$410.85M-11.7%	-$367.95M+4.3%	-$384.38M-5.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Denali Therapeutics Inc.'s cash flow data come from?: Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.